O	0	10	Randomized
O	10	11	,
O	12	19	placebo
O	19	20	-
O	20	30	controlled
O	30	31	,
O	32	38	double
O	38	39	-
O	39	44	blind
O	44	45	,
O	46	51	phase
O	52	54	II
O	55	60	study
O	61	63	of
B-intervention	64	72	axitinib
I-intervention	73	77	plus
I-intervention	78	87	docetaxel
O	88	94	versus
B-control	95	104	docetaxel
I-control	105	109	plus
I-control	110	117	placebo
O	118	120	in
O	121	129	patients
O	130	134	with
O	135	145	metastatic
O	146	152	breast
O	153	159	cancer
O	159	160	.

O	161	165	This
O	166	177	multicenter
O	177	178	,
O	179	189	randomized
O	189	190	,
O	191	197	double
O	197	198	-
O	198	203	blind
O	203	204	,
O	205	210	phase
O	211	213	II
O	214	219	study
O	220	228	assessed
O	229	235	safety
O	236	239	and
O	240	248	efficacy
O	249	251	of
O	252	260	axitinib
O	261	265	plus
O	266	275	docetaxel
O	276	278	in
O	279	289	metastatic
O	290	296	breast
O	297	303	cancer
O	304	305	(
O	305	308	MBC
O	308	309	)
O	309	310	.

B-eligibility	311	316	Women
I-eligibility	317	321	with
I-eligibility	322	325	MBC
O	326	330	were
O	331	339	randomly
O	340	348	assigned
O	349	350	2
O	350	351	:
O	351	352	1
O	353	355	to
O	356	363	receive
O	364	373	docetaxel
O	374	376	80
O	377	379	mg
O	379	380	/
O	380	382	m2
O	383	387	once
O	388	393	every
O	394	395	3
O	396	401	weeks
O	402	406	plus
O	407	415	axitinib
O	416	417	5
O	418	420	mg
O	421	426	twice
O	427	430	per
O	431	434	day
O	435	436	(
O	436	447	combination
O	448	451	arm
O	451	452	)
O	453	455	or
O	456	463	placebo
O	464	465	(
O	465	472	placebo
O	473	476	arm
O	476	477	)
O	477	478	,
O	479	488	following
O	489	490	a
O	491	495	lead
O	495	496	-
O	496	498	in
O	499	504	phase
O	505	506	I
O	507	512	trial
O	512	513	.

O	514	517	The
O	518	525	primary
O	526	529	end
O	530	535	point
O	536	539	was
B-outcome-Measure	540	544	time
I-outcome-Measure	545	547	to
I-outcome-Measure	548	559	progression
I-outcome-Measure	560	561	(
I-outcome-Measure	561	564	TTP
I-outcome-Measure	564	565	)
O	565	566	.

O	567	569	In
O	570	573	all
O	573	574	,
B-total-participants	575	578	168
O	579	587	patients
O	588	592	were
O	593	601	enrolled
O	601	602	;
B-intervention-participants	603	606	112
O	607	611	were
O	612	620	randomly
O	621	629	assigned
O	630	632	to
O	633	641	axitinib
O	642	645	and
B-control-participants	646	648	56
O	649	651	to
O	652	659	placebo
O	659	660	.

B-outcome	661	667	Median
I-outcome	668	671	TTP
O	672	675	was
O	676	687	numerically
O	688	694	longer
O	695	697	in
O	698	701	the
O	702	713	combination
O	714	717	arm
O	718	722	than
O	723	725	in
O	726	729	the
O	730	737	placebo
O	738	741	arm
O	742	743	(
B-iv-cont-median	743	744	8
I-iv-cont-median	744	745	.
I-iv-cont-median	745	746	1
O	747	748	v
B-cv-cont-median	749	750	7
I-cv-cont-median	750	751	.
I-cv-cont-median	751	752	1
I-cv-cont-median	753	759	months
O	759	760	)
O	760	761	,
O	762	765	but
O	766	770	this
O	771	781	difference
O	782	785	was
O	786	789	not
O	790	803	statistically
O	804	815	significant
O	816	817	(
O	817	823	hazard
O	824	829	ratio
O	829	830	,
O	831	832	1
O	832	833	.
O	833	835	24
O	835	836	;
O	837	839	95
O	839	840	%
O	841	843	CI
O	843	844	,
O	845	846	0
O	846	847	.
O	847	849	82
O	850	852	to
O	853	854	1
O	854	855	.
O	855	857	87
O	857	858	;
O	859	862	one
O	862	863	-
O	863	868	sided
O	869	870	P
O	871	872	=
O	873	874	.
O	874	877	156
O	877	878	)
O	878	879	.

O	880	883	The
O	884	894	difference
O	895	897	in
B-outcome	898	904	median
I-outcome	905	908	TTP
O	909	912	was
O	913	921	greatest
O	922	927	among
O	928	936	patients
O	937	940	who
O	941	944	had
O	945	953	received
O	954	959	prior
O	960	968	adjuvant
O	969	981	chemotherapy
O	982	983	(
B-iv-cont-median	983	984	9
I-iv-cont-median	984	985	.
I-iv-cont-median	985	986	2
O	987	988	v
B-cv-cont-median	989	990	7
I-cv-cont-median	990	991	.
I-cv-cont-median	991	992	0
I-cv-cont-median	993	999	months
O	999	1000	;
O	1001	1002	P
O	1003	1004	=
O	1005	1006	.
O	1006	1009	043
O	1009	1010	,
O	1011	1023	prespecified
O	1024	1032	subgroup
O	1033	1041	analysis
O	1041	1042	)
O	1042	1043	.

B-outcome	1044	1053	Objective
I-outcome	1054	1062	response
I-outcome	1063	1067	rate
O	1068	1071	was
O	1072	1078	higher
O	1079	1081	in
O	1082	1085	the
O	1086	1097	combination
O	1098	1101	arm
O	1102	1103	(
B-iv-bin-percent	1103	1105	41
I-iv-bin-percent	1105	1106	.
I-iv-bin-percent	1106	1107	1
I-iv-bin-percent	1107	1108	%
O	1109	1110	v
B-cv-bin-percent	1111	1113	23
I-cv-bin-percent	1113	1114	.
I-cv-bin-percent	1114	1115	6
I-cv-bin-percent	1115	1116	%
O	1116	1117	;
O	1118	1119	P
O	1120	1121	=
O	1122	1123	.
O	1123	1126	011
O	1126	1127	)
O	1127	1128	.

O	1129	1132	The
O	1133	1137	most
O	1138	1144	common
B-outcome	1145	1151	grades
I-outcome	1152	1153	3
I-outcome	1154	1156	to
I-outcome	1157	1158	4
I-outcome	1159	1168	treatment
I-outcome	1168	1169	-
I-outcome	1169	1176	related
I-outcome	1177	1184	adverse
I-outcome	1185	1191	events
O	1192	1193	(
O	1193	1204	combination
O	1204	1205	/
O	1205	1212	placebo
O	1212	1213	)
O	1214	1222	included
B-outcome	1223	1231	diarrhea
O	1232	1233	(
B-iv-bin-percent	1233	1235	10
I-iv-bin-percent	1235	1236	.
I-iv-bin-percent	1236	1237	8
I-iv-bin-percent	1237	1238	%
O	1238	1239	/
B-cv-bin-percent	1239	1240	0
I-cv-bin-percent	1240	1241	%
O	1241	1242	)
O	1242	1243	,
B-outcome	1244	1251	fatigue
O	1252	1253	(
B-iv-bin-percent	1253	1255	10
I-iv-bin-percent	1255	1256	.
I-iv-bin-percent	1256	1257	8
I-iv-bin-percent	1257	1258	%
O	1258	1259	/
B-cv-bin-percent	1259	1260	5
I-cv-bin-percent	1260	1261	.
I-cv-bin-percent	1261	1262	4
I-cv-bin-percent	1262	1263	%
O	1263	1264	)
O	1264	1265	,
B-outcome	1266	1276	stomatitis
O	1277	1278	(
B-iv-bin-percent	1278	1280	12
I-iv-bin-percent	1280	1281	.
I-iv-bin-percent	1281	1282	6
I-iv-bin-percent	1282	1283	%
O	1283	1284	/
B-cv-bin-percent	1284	1285	1
I-cv-bin-percent	1285	1286	.
I-cv-bin-percent	1286	1287	8
I-cv-bin-percent	1287	1288	%
O	1288	1289	)
O	1289	1290	,
B-outcome	1291	1300	mucositis
O	1301	1302	(
B-iv-bin-percent	1302	1303	9
I-iv-bin-percent	1303	1304	.
I-iv-bin-percent	1304	1305	0
I-iv-bin-percent	1305	1306	%
O	1306	1307	/
B-cv-bin-percent	1307	1308	0
I-cv-bin-percent	1308	1309	%
O	1309	1310	)
O	1310	1311	,
B-outcome	1312	1320	asthenia
O	1321	1322	(
B-iv-bin-percent	1322	1323	7
I-iv-bin-percent	1323	1324	.
I-iv-bin-percent	1324	1325	2
I-iv-bin-percent	1325	1326	%
O	1326	1327	/
B-cv-bin-percent	1327	1328	0
I-cv-bin-percent	1328	1329	%
O	1329	1330	)
O	1330	1331	,
O	1332	1335	and
B-outcome	1336	1348	hypertension
O	1349	1350	(
B-iv-bin-percent	1350	1351	4
I-iv-bin-percent	1351	1352	.
I-iv-bin-percent	1352	1353	5
I-iv-bin-percent	1353	1354	%
O	1354	1355	/
B-cv-bin-percent	1355	1356	0
I-cv-bin-percent	1356	1357	%
O	1357	1358	)
O	1358	1359	.

B-iv-bin-abs	1360	1365	Three
O	1366	1374	patients
O	1375	1377	in
O	1378	1381	the
O	1382	1393	combination
O	1394	1397	arm
O	1398	1409	experienced
B-outcome	1410	1417	serious
I-outcome	1418	1432	thromboembolic
I-outcome	1433	1439	events
O	1440	1441	(
B-iv-bin-abs	1441	1444	one
B-outcome	1445	1450	death
O	1450	1451	)
O	1451	1452	.

B-outcome	1453	1460	Febrile
I-outcome	1461	1472	neutropenia
O	1473	1476	was
O	1477	1481	more
O	1482	1490	frequent
O	1491	1493	in
O	1494	1497	the
O	1498	1509	combination
O	1510	1513	arm
O	1514	1515	(
B-iv-bin-percent	1515	1517	15
I-iv-bin-percent	1517	1518	.
I-iv-bin-percent	1518	1519	3
I-iv-bin-percent	1519	1520	%
O	1521	1522	v
B-cv-bin-percent	1523	1524	7
I-cv-bin-percent	1524	1525	.
I-cv-bin-percent	1525	1526	1
I-cv-bin-percent	1526	1527	%
O	1527	1528	)
O	1528	1529	;
O	1530	1535	rates
O	1536	1538	of
O	1539	1544	other
O	1545	1556	hematologic
O	1557	1567	toxicities
O	1568	1572	were
O	1573	1583	comparable
O	1583	1584	.

O	1585	1594	Increased
B-outcome	1595	1603	toxicity
O	1604	1608	with
O	1609	1617	axitinib
O	1618	1621	was
O	1622	1631	generally
O	1632	1639	managed
O	1640	1642	by
O	1643	1647	dose
O	1648	1657	reduction
O	1658	1661	and
O	1661	1662	/
O	1662	1664	or
O	1665	1671	growth
O	1672	1678	factor
O	1679	1686	support
O	1686	1687	.

O	1688	1691	The
O	1692	1700	addition
O	1701	1703	of
O	1704	1712	axitinib
O	1713	1715	to
O	1716	1725	docetaxel
O	1726	1729	did
O	1730	1733	not
O	1734	1741	improve
O	1742	1745	TTP
O	1746	1748	in
O	1749	1754	first
O	1754	1755	-
O	1755	1759	line
O	1760	1763	MBC
O	1764	1773	treatment
O	1773	1774	.

O	1775	1786	Combination
O	1787	1794	therapy
O	1795	1798	may
O	1799	1801	be
O	1802	1806	more
O	1807	1816	effective
O	1817	1819	in
O	1820	1828	patients
O	1829	1839	previously
O	1840	1847	exposed
O	1848	1850	to
O	1851	1859	adjuvant
O	1860	1872	chemotherapy
O	1872	1873	.
